Patents Assigned to OBLIQUE THERAPEUTICS AB
-
Patent number: 11912765Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.Type: GrantFiled: September 29, 2021Date of Patent: February 27, 2024Assignee: OBLIQUE THERAPEUTICS ABInventors: Owe Orwar, Carolina Trkulja
-
Publication number: 20230109318Abstract: The present invention relates to antibodies that bind to certain oncogenic mutant forms of KRAS. The invention also relates to certain epitopes of oncogenic mutant forms of KRAS. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic purposes, for example in the treatment of cancer.Type: ApplicationFiled: February 24, 2021Publication date: April 6, 2023Applicant: OBLIQUE THERAPEUTICS ABInventors: Carolina TRKULJA, Max DAVIDSON, Owe ORWAR
-
Patent number: 11408883Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.Type: GrantFiled: October 6, 2017Date of Patent: August 9, 2022Assignee: OBLIQUE THERAPEUTICS ABInventors: Owe Orwar, Carolina Trkulja, Max Davidson, Jessica Hägglund
-
Publication number: 20220119348Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.Type: ApplicationFiled: October 29, 2021Publication date: April 21, 2022Applicant: Oblique Therapeutics ABInventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
-
Publication number: 20220073607Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.Type: ApplicationFiled: September 29, 2021Publication date: March 10, 2022Applicant: OBLIQUE THERAPEUTICS ABInventors: Owe ORWAR, Carolina TRKULJA
-
Patent number: 11208384Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.Type: GrantFiled: February 7, 2018Date of Patent: December 28, 2021Assignee: Oblique Therapeutics ABInventors: Benjamin Pelcman, Owe Orwar, William Stafford, Kjell Andersson
-
Patent number: 11168069Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.Type: GrantFiled: February 7, 2018Date of Patent: November 9, 2021Assignee: Oblique Therapeutics ABInventors: Benjamin Pelcman, William Stafford
-
Patent number: 11161901Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.Type: GrantFiled: March 31, 2016Date of Patent: November 2, 2021Assignee: OBLIQUE THERAPEUTICS ABInventors: Owe Orwar, Carolina Trkulja
-
Patent number: 11161815Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.Type: GrantFiled: February 7, 2018Date of Patent: November 2, 2021Assignee: Oblique Therapeutics ABInventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
-
Patent number: 11028067Abstract: There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings provided in the description, which compounds are useful in the treatment of cancers.Type: GrantFiled: February 7, 2018Date of Patent: June 8, 2021Assignee: Oblique Therapeutics ABInventors: Benjamin Pelcman, Edgars Suna, William Stafford, Martins Priede
-
Publication number: 20200041499Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.Type: ApplicationFiled: October 6, 2017Publication date: February 6, 2020Applicant: OBLIQUE THERAPEUTICS ABInventors: Owe ORWAR, Carolina TRKULJA, Max DAVIDSON, Jessica HÄGGLUND
-
Publication number: 20190194320Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein and the identification of sites on the protein that are cut by the protease(s) used. The invention also relates to antibodies which bind to epitopes that have been identified by methods of the invention.Type: ApplicationFiled: September 1, 2017Publication date: June 27, 2019Applicant: OBLIQUE THERAPEUTICS ABInventors: Owe ORWAR, Carolina TRKULJA, Max DAVIDSON
-
Publication number: 20180111990Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.Type: ApplicationFiled: March 31, 2016Publication date: April 26, 2018Applicant: OBLIQUE THERAPEUTICS ABInventors: Owe ORWAR, Carolina TRKULJA